By Melissa Badamo - Last Updated: June 12, 2024
The incidence of bleeding events in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving Bruton’s tyrosine kinase inhibitors (BTKis) is 26.6 per 100 patients per year, according to a study presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.
The retrospective cohort study, led by Javid Moslehi, MD, of the University of California, utilized the claims-linked Premier PINC AI Healthcare Database of 2,091 adult patients with a diagnosis of CLL or SLL from July 1, 2016, to March 31, 2022. Patient follow-up spanned from initial BTKi prescription fill to BTKi discontinuation, death, or the end of the study period. BTKi treatments included ibrutinib (86.3%), acalabrutinib (13.1%), and zanubrutinib (<1.0%).
The researchers assessed patient comorbidities, treatments, and bleeding events using diagnosis and procedure codes and prescription claims. They also used the Cox proportional hazards regression model to assess the multivariable-adjusted risk for bleeding events.
Bleeding events occurred in 526 (25.2%) patients during an average 14.2 months of BTKi exposure. The incidence of bleeding events was 26.6 per 100 person-years (PYs) overall, 37.2 per 100 PYs in patients with anticoagulant or antiplatelet use, and 22.0 per 100 PYs in patients without anticoagulant or antiplatelet use. Less than 0.3% of patients experienced fatal bleeding.
In adjusted models, the risk of first bleeding event was higher for patients with anticoagulant use (hazard ratio [95% CI], 2.33 [1.83-2.98]), patients 65 years or older (1.32 [1.14-1.53]), women (1.28 [1.10-1.48]), and patients with a history of bleeding (2.27 [1.87-2.76]), ulcers (2.21 [1.06-4.63]), or myocardial infarction (1.74 [1.31-2.33]; all P≤.05).
Reference
Moslehi JJ, Wahlstrom SK, Teschemaker A, et al. Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi. Abstract #7052. Presented at the 2024 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago, Illinois
Original Source: Risk of Bleeding Events in Patients With CLL Receiving BTKis | Blood Cancers Today